Biogen Inc

16 de jul. de 2026, 19:02 UTC

Biogen partners with Synapticure to launch a virtual ataxia care program. Shares are higher today, reflecting positive sentiment since Wednesday's close.

15 de jul. de 2026, 23:36 UTC

Biogen Inc. shares declined in after-market trading, reflecting ongoing weakness amid broader market caution related to geopolitical tensions involving the U.S. and Iran.

14 de jul. de 2026, 23:41 UTC

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

13 de jul. de 2026, 23:06 UTC

Biogen received FDA approval for LEQEMBI IQLIK, a subcutaneous Alzheimer's treatment, boosting shares modestly higher in after-market trading.

10 de jul. de 2026, 21:01 UTC

Biogen Inc shares declined in after-market trading, reversing an initial uptick and nearing the lower end of their one-month trading range. No specific news was identified.

9 de jul. de 2026, 23:46 UTC

Biogen Inc shares are trading lower in after-market hours, continuing a trend of five consecutive daily declines without any specific news to explain the movement.

8 de jul. de 2026, 23:56 UTC

Biogen Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing lower, with no specific news identified for the decline.

7 de jul. de 2026, 23:31 UTC

Biogen Inc shares are higher in after-market trading following Tuesday's close, amid broader market volatility but stable performance above its 20-day moving average.

6 de jul. de 2026, 23:56 UTC

Biogen Inc. shares are higher in after-market trading, reflecting a slight upward movement since Monday's close and settling near the upper end of their one-month range.

2 de jul. de 2026, 22:16 UTC

Biogen Inc shares are lower in after-market hours, reflecting a decline since Thursday's close amid mixed market sentiment and a weaker jobs report.

1 de jul. de 2026, 20:07 UTC

Biogen Inc. shares are lower as broader market sell-offs raise volatility. Barclays notes vulnerabilities in U.S. equity markets affecting investor sentiment.

30 de jun. de 2026, 19:56 UTC

Biogen will present new Alzheimer’s data at the AAIC 2026, including findings from the Phase 2 CELIA study and LEQEMBI analyses. Shares are higher today.

29 de jun. de 2026, 23:02 UTC

Biogen will present new Alzheimer’s data at AAIC 2026, but shares are lower in after-market hours amid broader market volatility and geopolitical tensions.

26 de jun. de 2026, 19:51 UTC

Biogen Inc pauses investment in most legacy Apellis programs, aligning with current objectives. Shares are higher today, reflecting positive investor response to the restructuring.

25 de jun. de 2026, 22:36 UTC

Biogen Inc's shares are higher in after-market trading, reflecting a notable upward trajectory since Thursday's close amid mixed broader market results.

24 de jun. de 2026, 20:04 UTC

Biogen Inc shares are higher today, supported by a broader rally in the Biotechnology sector and increased interest noted on social media.

23 de jun. de 2026, 23:21 UTC

Biogen Inc shares are higher in after-market trading, reaching a session high. No specific news was identified to explain the unusual price movement.

22 de jun. de 2026, 23:46 UTC

Biogen Inc. shares traded lower in after-market hours following modest fluctuations since Monday's close, with the price dipping after a brief session high.

18 de jun. de 2026, 20:05 UTC

Biogen Inc. plans to acquire RayThera Inc. for up to $1 billion, but shares are declining amid broader Biotechnology sector weakness.

17 de jun. de 2026, 23:06 UTC

Biogen Inc announced a definitive agreement to acquire RayThera Inc. for up to $1 billion, enhancing its immunology pipeline. Shares are trading higher after the news.

16 de jun. de 2026, 19:46 UTC

Biogen Inc. shares are lower amid an investigation announcement linked to the Phase 2 CELIA study's failure and failed negotiations over Skyclarys.

12 de jun. de 2026, 19:51 UTC

Biogen Inc. shares are higher today, breaking a recent trend. Broader market sentiment is shaped by inflation concerns and optimism about upcoming IPOs.

11 de jun. de 2026, 19:51 UTC

Biogen Inc is advancing as the biotechnology sector gains. Earlier in the session, shares pulled back from a high but resumed their upward trajectory.

10 de jun. de 2026, 19:36 UTC

Biogen Inc. is under investigation by Bronstein, Gewirtz & Grossman, LLC, following disappointing Phase 2 CELIA study results. Shares are trading lower amid ongoing scrutiny.

9 de jun. de 2026, 23:16 UTC

Biogen Inc. shares declined in after-market trading, moving lower since Tuesday's close. The asset remains above its 20-day moving average.

8 de jun. de 2026, 20:06 UTC

Biogen Inc. shares are lower amid negative sentiment over its Phase 2 CELIA study results, despite a recent upgrade to a Buy rating.

5 de jun. de 2026, 19:16 UTC

Biogen shares are gaining following FDA's Breakthrough Therapy Designation for salanersen in spinal muscular atrophy, despite pulling back from earlier session highs.

4 de jun. de 2026, 22:06 UTC

Biogen Inc. received FDA Breakthrough Therapy Designation for salanersen, aimed at treating spinal muscular atrophy, with shares trading higher in after-market hours.

3 de jun. de 2026, 20:03 UTC

Biogen Inc. announced fourteen abstracts accepted for presentation at upcoming nephrology congresses, contributing to higher trading shares amid positive market sentiment.

2 de jun. de 2026, 20:06 UTC

Biogen Inc. shares declined during Tuesday's session, continuing a trend of lower closes, amid broader weakness in the biotechnology sector.